Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029

All NewsNovember 10, 2025

Galecto stock jumps after acquiring Damora Therapeutics and raising $285 million to advance blood cancer programs through 2029.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent